Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma

Evofosfamide (TH-302) is a clinical-stage hypoxia-activated prodrug of a DNA-crosslinking nitrogen mustard that has potential utility for human papillomavirus (HPV) negative head and neck squamous cell carcinoma (HNSCC), in which tumor hypoxia limits treatment outcome. We report the preclinical effi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCI Insight
Main Authors: Jamieson, Stephen M.F., Tsai, Peter, Kondratyev, Maria K., Budhani, Pratha, Liu, Arthur, Senzer, Neil N., Chiorean, E. Gabriela, Jalal, Shadia I., Nemunaitis, John J., Kee, Dennis, Shome, Avik, Wong, Way W., Li, Dan, Poonawala-Lohani, Nooriyah, Kakadia, Purvi M., Knowlton, Nicholas S., Lynch, Courtney R.H., Hong, Cho R., Lee, Tet Woo, Grénman, Reidar A., Caporiccio, Laura, McKee, Trevor D., Zaidi, Mark, Butt, Sehrish, Macann, Andrew M.J., McIvor, Nicholas P., Chaplin, John M., Hicks, Kevin O., Bohlander, Stefan K., Wouters, Bradly G., Hart, Charles P., Print, Cristin G., Wilson, William R., Curran, Michael A., Hunter, Francis W.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6141174/
https://ncbi.nlm.nih.gov/pubmed/30135316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.122204
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados